Ozanimod (Zeposia) became the third oral S1P modulator approved by the FDA for the treatment of multiple sclerosis,
Rahman Gul, PharmD Candidate
Advertisement
Articles by Rahman Gul, PharmD Candidate
Advertisement
Latest Updated Articles
Ozanimod: Treatment for Relapsing Forms of Multiple SclerosisAugust 12th 2020
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5